Beyond the Endpoint

Anuja Dokras, MD, MHCI, PhD, joins Emily O'Brien and new co-host Daniel Edmonston to explain why PCOS is now PMOS, polyendocrine metabolic ovarian syndrome. She traces the global effort behind the new name and how it could reduce stigma, improve frontline care, and open doors to new research funding. https://dcri.org/blog/s3-ep-4-whats-name-journey-pcos-pmos

Hosts Manesh Patel and Emily O'Brien look past the headlines on Novartis' Lp(a) drug trial results, AI agents in medicine, the FDA's Operation Trailblazer to speed up clinical trials, Dolly Parton's support for COVID research, and the case for steady NIH funding.
https://dcri.org/blog/s3-ep-3-beyond-headlines

Three former DCRI executive directors, Bob Harrington, Eric Peterson, and Lesley Curtis, join Beyond the Endpoint for part two of the institute's 30th anniversary series. They reflect on growth, crisis, inconvenient truths, and the culture they believe will carry DCRI through whatever comes next. https://dcri.org/blog/s3-ep-2-critical-filling-30-years-harrington-peterson-curtis

To mark DCRI's 30th anniversary, this first episode in a two-part series features founding director Robert Califf and current Executive Director Adrian Hernandez as they look back at the institute's evolution and ahead to its future. Part two arrives Sept. 23. https://dcri.org/blog/s3-ep-1-foundation-future-30-years-califf-hernandez

In this Beyond the Headlines episode, we examine the FDA's push for real-time clinical trial data, an executive order making psychedelic research a federal priority, advances in CAR T-cell therapy for autoimmune conditions, and viral claims about antihistamines as a treatment for premenstrual dysphoric disorder.

🔗 Access resources related to this episode: https://dcri.org/blog/s2-ep-16-beyond-headlines